Skip to main content
. 2015 Dec 30;7(5):5598–5612. doi: 10.18632/oncotarget.6798

Figure 6. Sensitivity of cancer cells to the pan-enolase inhibitor PhAH.

Figure 6

A. Analysis of enolase activity measured as the rate of NADH oxidation in normal human fibroblasts, HPDE, CFPAC-1, MDA-MB-231 and NCI-H441 cell line protein extracts treated for 6 h with 50 μM PhAH. B.–F. Time- and dose-dependent effect of enolase pharmacological inhibitor (PhAH) on cell survival assessed by MTT assay. Cells were starved and MTT solution was added every 24 h after serum replenishment and PhAH boost. OD values were measured at 570 nm. Curves were compared by two-way ANOVA, ***p < 0.001 relative to untreated.